Clinical Trial Update: Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the relative bronchodilating effects of formoterol when delivered via Symbicort pMDI versus Oxis Turbuhaler in stable asthma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Oxis Turbuhaler (formoterol)
• Symbicort (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Stable Asthma | Phase 2 | Status: COMPLETED